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Manuscript rece
accepted August 1olchicine, a natural and ancient drug still used today, is traditionally considered the staple therapy for gout and
a second-line treatment for pericarditis, as well as a basic part of familial Mediterranean fever and Behcet’s disease
management. It is commonly classiﬁed as an anti-inﬂammatory agent, although its mechanism of action does not
involve the arachidonic acid pathway affected by non-steroid anti-inﬂammatory drugs and glucocorticoids. Colchicine
inhibits microtubule polymerization by binding to tubulin, thus affecting any process that requires cytoskeletal
changes, including cell mitosis and neutrophil motility. Recent studies suggest that colchicine may prove to be
useful in a much wider spectrum of cardiovascular diseases than previously suspected, rekindling the interest in this
old drug. In this review we brieﬂy present the biochemical characteristics, mechanism of action and side-effects of
colchicine, as well as examine what is currently known about the promising role of colchicine in cardiovascular
medicine beyond pericardial disease. (J Am Coll Cardiol 2013;62:1817–25) ª 2013 by the American College of
Cardiology FoundationColchicine, the extract from the Colchicum autumnale plant
(autumn crocus), used by ancient Greeks more than 2,000
years ago (1), is one of the oldest known drugs still
prescribed today. In 1820, the French chemists P. S. Pel-
letier and J. B. Caventou were the ﬁrst to extract colchicine
as the active alkaloid of colchicum (2). While colchicine in
combination with probenecid has been approved by the U.S.
Food and Drug Administration (FDA) prior to 1982, until
recently colchicine was widely used for the treatment of gout
without ofﬁcial FDA evaluation. On July 30, 2009, the
FDA approved colchicine for the treatment of familial
Mediterranean fever and acute gout and for prophylaxis
against gouty arthritis (3). Colchicine is also used today as
a second-line treatment for pericarditis (4).
Colchicine is widely used in in vitro experiments requiring
cytoskeleton disruption. Since colchicine was “ofﬁcially”
endorsed by the FDA, several human studies have emerged
examining the possible potential of this low-cost drug for
other clinical indications. In this review we refer to studies
claiming a wider role for colchicine in cardiovascular disease,
beyond traditional indications in pericarditic syndromes, asment of Cardiology, Athens General Hospital “G. Gennimatas”,
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3, 2013.well as examine whether our current knowledge about
colchicine mechanisms of action can offer insights relevant
to clinical ﬁndings. It is true that data from really large,
randomized trials of colchicine for potential novel indica-
tions in cardiovascular disease with hard clinical endpoints
are lacking. As a result, a true systematic review or a meta-
analysis (with the statistical processing that these terms
imply) is implausible at the moment. This does not mean,
however, that the existing evidence is negligible. It is clear
from Table 1 that a number of well-planned and well-
conducted studies have been published. For these reasons,
the scope of the present review encompasses 2 main goals:
1) presenting an exhaustive account of clinical studies indi-
cating potential new uses of colchicine in heart disease; and
2) stimulating interest among cardiovascular specialists for
this old and, possibly, underutilized medicine.
Pharmacokinetics
Colchicine is a lipid-soluble drug with a [pKa] ¼ 12.8 that
can penetrate easily into body tissues after uptake in the
jejunum and ileum (5). After oral ingestion it has a 44%
bioavailability and binds relatively weakly to albumin (32%
bound) (6). Its peak plasma concentration occurs in about
1 h, with a long terminal half-life (5). Colchicine enters
red blood cells and leucocytes where it remains in much
higher concentrations than the plasma (6). Colchicine can be
found inside leukocytes for up to several days after admin-
istration (7), with this local pooling and long half-life
explaining why a once- or twice-daily dosage scheme is
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1818enough for inﬂammation sup-
pression. Colchicine is predomi-
nantly eliminated by the liver,
through biliary excretion and
metabolism by the hepatic cyto-
chrome CYP3A4 (8), with about
10% to 20% of the drug secreted
unchanged in urine. Peak plasma
concentration and plasma half-
life can be signiﬁcantly pro-
longed in patients with liver or
renal failure or in the elderly (9),
with side effects appearing even
at low doses.
Colchicine has a relatively low
therapeutic index, with effective
steady-state plasma concentrations ranging between 0.5 and
3 ng/ml. A signiﬁcant percentage of patients report adverse
effects, mainly gastrointestinal symptoms, serious enough to
cause discontinuation of therapy even at low daily doses.
This is offset by the fact that in patients who tolerate
colchicine, it can be administered for long periods of time
(even years as experience in familial Mediterranean fever has
shown) without any notable long-term side effects, con-
trasting sharply with nonsteroidal anti-inﬂammatory drugs
(NSAIDs) and glucocorticoids. Rare side effects of chronic
colchicine administration include liver failure, bone marrow
depression, which may manifest as leucopenia or aplastic
anemia, and rhabdomyolysis (10).
Mechanisms of Action
Due to the rapid suppression of gouty arthritis without
interfering with uric acid kinetics, colchicine is generally
classiﬁed as an anti-inﬂammatory agent in the medical liter-
ature. However, it should be noted that the characterization
“anti-inﬂammatory” deﬁnes only part of this drug’s actions.
Colchicine is unique in that its mechanism of action does not
involve the arachidonic acid pathway affected by NSAIDs
and glucocorticosteroids. Colchicine binds to unpolymerized
tubulin heterodimers, forming a stable complex that effec-
tively inhibits microtubule dynamics upon binding to micro-
tubule ends. It causes microtubule depolymerization by
inhibiting lateral contacts between protoﬁlaments (11), thus
affecting any process that requires cytoskeletal changes,
including cell mitosis, exocytosis, and neutrophil motility (8).
Microtubule structure is illustrated in Figure 1, while the
spatial interaction of colchicine and tubulin subunits is
illustrated in Figure 2. At low concentrations, colchicine
inhibits the formation of microtubules while at higher
concentrations it promotes their depolymerization (Fig. 3)
(11). Colchicine has been found to impair adhesion of
neutrophils to the vascular endothelium. In vitro experiments
have shown that colchicine diminishes endothelial selectin
family-dependent adhesiveness, affecting both endothelial E-
selectin and, at higher concentrations, neutrophil L-selectinsurface expression (12). It has also been found to increase
leukocyte cyclic adenosine monophosphate levels, inhibit
interleukin-1 (IL-1) production by activated neutrophils and
down-regulate tumor necrosis factor alpha receptors in
macrophages and endothelial cells (8).
Recently, colchicine was associated with another anti-
inﬂammatory mechanism in gout. Colchicine appears to
block the crystal-induced activation of the NLRP3 inﬂam-
masome protein complex, which proteolytically cleaves
caspase-1 and leads to secretion of proinﬂammatory cyto-
kines IL-1b and IL-18 (13). Other studies have shown the
close interaction of microtubules and NLRP3 inﬂamma-
some activation (14). Inﬂammasomes have recently been
associated with atherosclerotic disease (15) and cardiac
ischemia/reperfusion injury (16). However, any direct effects
of colchicine on inﬂammasome activation in the heart or
vessels have not been studied.
Depending on concentration, colchicine could have other
effects as well. A study by Ben-Chetrit et al. (17) showed that
colchicine has the potential to induce changes at the tran-
scriptional level (affecting cell-cycle-regulatory genes) in human
umbilical vein endothelial cell line cells. However, the concen-
tration used was almost 100-fold the average plasma concen-
tration in patients under colchicine treatment, therefore it is not
clear if these results have any clinicalmeaning. In another recent
in vitro study, colchicine prevented the contractile and mito-
chondrial dysfunction caused by the macrophage migration
inhibitory factor in human atrial cells (18).
Colchicine and Pericarditis
Until relatively recently, colchicine use in treating idiopathic
pericarditis was empiric, based on small-scale studies and
anecdotal reports (19). In 2004, the European Society of
Cardiology guidelines on the diagnosis and management of
pericardial diseases endorsed colchicine as an acceptable
second-line treatment in acute and recurrent pericarditis
(20). In the subsequent COPE (Colchicine in Acute Peri-
carditis) and CORE (Colchicine for Recurrent Pericarditis)
and the more recent and almost synonymous CORP trials,
colchicine as an adjunct therapy to NSAIDs was found to
be an effective addition to treatment in this clinical setting
(21–23). In the COPE trial the addition of colchicine to
aspirin therapy in 120 patients with a ﬁrst episode of acute
pericarditis was associated with a faster symptomatic relief
(36.7% of patients in the aspirin group vs. 11.7% in the
aspirin plus colchicine group after 72 h) as well as with
signiﬁcantly less recurrent pericarditis episodes over the
subsequent 18 months (10.7% vs. 32.3% in the aspirin
group). The beneﬁts of colchicine addition in prevention
and treatment of recurrent pericarditis were also veriﬁed in
the CORE and CORP trials. Today, when treating peri-
cardial inﬂammation, colchicine is preferred over cortico-
steroids for coadministration with NSAIDs (24). For
a thorough study of the use of colchicine in pericarditis,
excellent reviews have been published (25).
Table 1 Important Clinical Studies Examining the Role of Colchicine Administration in Cardiovascular Disease, Beyond Pericarditic Syndromes
First Author (Ref.#) Study Design Clinical Setting Summary Patient Number
Colchicine Dose and
Duration of Treatment
Imazio et al. (29) Secondary analysis
of a multicenter,
double-blind,
randomized trial
Post-cardiothoracic
-surgery atrial
ﬁbrillation
Reduction of post-operative atrial ﬁbrillation
incidence (12.0% vs. 22.0%; p ¼ 0.021;
relative risk reduction: 45%) with shorter
in-hospital stay (9.4  3.7 days vs. 10.3  4.3
days; p ¼ 0.040) and rehabilitation
(12.1  6.1 days vs. 13.9  6.5 days; p ¼ 0.009).
336 Loading dose 1.0 mg
twice on the ﬁrst day,
followed by 0.5 mg
twice daily for 1 month
Deftereos et al. (36) Two-center,
prospective randomized,
double-blind study
Post-ablation recurrence
of atrial ﬁbrillation
Prevention of early atrial ﬁbrillation recurrences
after pulmonary vein isolation (16% vs. 33.5%
placebo; odds ratio: 0.38; 95% conﬁdence
interval: 0.18 to 0.80) in the absence of
antiarrhythmic drug treatment.
161 0.5 mg twice
daily for 3 months
Nidorf and
Thompson (56)
Single-center
open-label pilot study
Stable coronary
artery disease
Decrease of hs-CRP in patients with clinically
stable coronary artery disease and increased
hs-CRP, independent of aspirin and atorvastatin
use (mean baseline hs-CRP change from
4.58  2.05 mg/l to 1.78  1.38 mg/l; p <0.001).
64 0.5 mg twice
daily for 1 month
Nidorf et al. (57) PROBE (Prospective,
Randomized,
Observer-Blinded
Endpoint) trial
Stable coronary
artery disease
Colchicine in addition to statins and other
standard secondary prevention therapies
was associated with reduced rate of the
composite of acute coronary syndrome,
out-of-hospital cardiac arrest, or
noncardioembolic ischemic stroke
(hazard ratio: 0.33; 95% conﬁdence
interval: 0.18 to 0.59; p < 0.001).
532 0.5 mg daily for a
median of 3 years
Crittenden et al. (58) Retrospective,
cross-sectional study
Myocardial
infarction
Gout patients who took colchicine had a
signiﬁcantly lower prevalence of
myocardial infarction (1.2% in
the colchicine vs. 2.6% in the
no-colchicine group; p ¼ 0.03) and
exhibited trends toward reduced
all-cause mortality and lower CRP levels.
1,288 d
Raju et al. (59) Single-center
double-blind pilot
randomized
controlled trial
Acute coronary
syndrome or stroke
No evidence that colchicine compared
with placebo suppresses inﬂammation
in patients with acute coronary syndrome
or acute ischemic stroke.
80 1.0 mg daily for
30 days
O’Keefe et al. (72) Double-blind,
prospective,
randomized trial
Plain old balloon
angioplasty
Colchicine 0.6 mg twice daily for 6 months
after elective coronary balloon angioplasty
was ineffective for preventing restenosis.
197 0.6 mg twice daily
for 6 months
Freed et al. (73) Open-label
pilot trial
Plain old balloon
angioplasty
The combined administration of lovastatin,
enalapril, and colchicine does not appear
to inhibit restenosis after PTCA.
50 0.6 mg twice daily
for at least 4 months
Deftereos et al. (76) Double-blind,
prospective,
randomized trial
Percutaneous coronary
intervention with bare-metal
stent implantation
Colchicine is associated with less neointimal
hyperplasia and reduced in-stent restenosis
rate when administered to diabetic patients
after PCI with BMS (16% vs. 33% in controls
(p ¼ 0.007; odds ratio: 0.38; 95%
conﬁdence interval: 0.18 to 0.79)
196 0.5 mg twice daily
for 6 months
BMS ¼ bare-metal stent(s); hs-CRP ¼ high-sensitivity C-reactive protein; PCI ¼ percutaneous coronary intervention; PTCA ¼ percutaneous transluminal coronary angioplasty.
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Figure 1 Microtubule Structure
Tubulin is composed of 2 protein subunits, alpha and beta, which form hetero-
dimers. These are polymerized head-to-tail to form protoﬁlaments. Thirteen pro-
toﬁlaments are linked laterally, forming the 3-dimensional cylinder of the
microtubule with b-tubulin exposed at the microtubule plus (D) end (yellow
circles) and a-tubulin exposed at the microtubule minus (–) end (red circles).
Figure 3 Colchicine Mechanism of Action
Colchicine (Col) binds unpolymerized tubulin at the a/b-tubulin interface and is
then incorporated into microtubules. The binding of colchicine to the microtubule
(D) end decreases microtubule dynamicity. At higher concentrations, lateral
contacts between protoﬁlaments are disrupted, resulting in microtubule
depolymerization.
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Post-operative atrial ﬁbrillation. Atrial ﬁbrillation (AF)
after cardiac surgery (post-operative atrial ﬁbrillation
[POAF]), occurring in 10% to 65% of all cardiac surgery
patients (26), is a signiﬁcant problem, in view of theFigure 2 Colchicine Binding Site
A computer-generated model of colchicine in relation to tubulin subunits.
(Reprinted with permission from Tripathi A, Fornabaio M, Kellogg GE, et al. Docking
and hydropathic scoring of polysubstituted pyrrole compounds with antitubulin
activity. Bioorg Med Chem 2008;16:2235–42).associated increased morbidity and mortality and length-
ening of hospital stays (27). Besides the obvious atrial
trauma, other factors have also been implicated in its
pathogenesis, including surgery-related pericardial inﬂam-
matory processes, autonomic disturbance, and changes in
plasma volume regulation (28).
Colchicine came to the forefront in a pivotal substudy of
the COPPS (Colchicine for the Prevention of the Post-
pericardiotomy Syndrome) trial by Imazio et al. (29),
a multicenter, double-blind, randomized trial. The admin-
istration of colchicine from post-operative day 3 and for up
to 1 month was associated with 45% reduction in the inci-
dence of POAF, followed not unexpectedly by reduced in-
hospital and rehabilitation stay, while halving the mean
duration of POAF episodes. There has been some contro-
versy (30) as to whether post-operative day 3 is the optimum
time for treatment initiation. The COPPS main study was
designed to test colchicine efﬁcacy in preventing post-
pericardiotomy syndrome and not POAF. The incidence
of POAF is high on the ﬁrst few post-operative days and this
was reﬂected in the fact that 43% of the POAF episodes
documented in the COPPS substudy occurred before the
onset of colchicine treatment. It is reasonable to assume that
an earlier (maybe even pre-operative) initiation of treatment
would be even more effective, but this remains unproven. In
any case, more answers are expected from the COPPS-2 trial
(a multicenter study planning to include 360 cardiac surgery
patients), which will have POAF as a primary endpoint.
JACC Vol. 62, No. 20, 2013 Deftereos et al.
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1821Another plausible hypothesis is that colchicine exerted its
prophylactic action, at least in part, thanks to its anti-
inﬂammatory properties. Although the COPPS substudy
did not correlate POAF reduction with the fall of inﬂam-
matory markers, atrial or possibly pericardial inﬂammation
seems to have a causative relationship with POAF. The peak
incidence of POAF has been correlated with the peak
concentration rise of C-reactive protein (CRP) in cardiac
surgery patients (31) and elevated white blood cell counts
(32). However, the strongest evidence in favor of this
proposition comes from the fact that glucocorticoids
signiﬁcantly reduced POAF incidence in animal models
(33,34) and clinical studies (35).
Colchicine for AF recurrence after ablation therapy. The
positive results of the COPPS substudy were followed by
an investigation by our group into the possible role of
colchicine administration in another population at risk for
AF, namely patients who have undergone pulmonary vein
isolation as part of AF ablation therapy (36). In this
prospective randomized double-blind study, the adminis-
tration of colchicine monotherapy for 3 months was asso-
ciated with preventing AF recurrences after pulmonary vein
isolation within that timeframe (16% colchicine vs. 33.5%
for the placebo group). Kaplan-Meier curves of the cumu-
lative hazard of AF recurrence are illustrated in Figure 4.
This effect was accompanied by a signiﬁcant decrease in
inﬂammatory mediators, IL-6 and CRP. This study was
prompted by the strong link between inﬂammation and early
post-ablation AF recurrence (37), with persistently elevated
CRP for up to 3 months after AF ablation (38), and fol-
lowed another study, by Koyama et al. (39). In that study,
patients undergoing pulmonary vein isolation received
hydrocortisone (2 mg/kg) on the day of the procedure andFigure 4
Colchicine for Prevention of
Post-Ablation Atrial Fibrillation Recurrence
Kaplan-Meier curves of the cumulative hazard of early atrial ﬁbrillation (AF) recur-
rence after pulmonary vein isolation. Reprinted with permission from Deftereos
et al. (36).prednisolone (0.5 mg/kg/day) per os for the following 3
days. The prevalence of immediate post-ablation AF (<3
days after ablation) was signiﬁcantly lower in the cortico-
steroid (7%) than in the placebo group (31%). The preva-
lence however of early post-ablation AF (4 to 30 days after
ablation), when patients were not receiving corticosteroids,
was the same between the 2 groups.
In retrospect, it could be expected that patients undergoing
AF ablation therapy would beneﬁt from inﬂammation
suppression, similarly to post–cardiac surgery patients,
although early post-ablation AF occurrence does not neces-
sarily have the same causes as POAF. AF ablation is a mini-
mally invasive procedure where there is local inﬂammation, but
no excessive catecholamine production, ﬂuid shift or major
surgery trauma. So, the key mechanism is probably inﬂam-
mation, either alone or together with the remodeling of ablated
areas. Inﬂammation has been shown to be a cause for AF
(40,41), leading to adverse atrial remodeling and making the
atria substrate vulnerable to AF. However, each episode of AF
may become responsible for more adverse structural and
electrical remodeling, creating a vicious circle (42,43). In the
5A (Antiarrhythmics After Ablation of Atrial Fibrillation)
study, the only predictor of a 6-month free AF period was the
absence of early (<6 weeks) post-ablation AF recurrence (44).
Therefore, although our group administered colchicine for
3 months post-ablation (36), positive results may persist
for a longer period of time. This expectation, however, will
have to be validated with follow-up studies (our group has
unpublished data indicating that the beneﬁt of colchicine in
terms of lower AF recurrence rate extends well beyond 1 year
after a single ablation procedure in the absence of antiar-
rhythmic treatment).
While inﬂammation seems to be causatively linked to
early post-ablation AF, and colchicine administration is
a promising prevention strategy, the optimum duration and
dose of treatment have not been deﬁned. A shorter colchi-
cine treatment period has not been tested but, if effective,
would certainly have advantages over a 90-day treatment,
especially since a considerable proportion of patients (12.3%)
in our study (36) discontinued colchicine, mainly due to
gastrointestinal complaints.
The anti-inﬂammatory properties of colchicine do not
preclude other mechanisms playing a role in the reduction of
POAF or post-ablation AF, besides inﬂammation suppres-
sion. In several in vitro or animal studies, colchicine
administration has been shown to exert electrophysiological
effects related to cytoskeletal disruption. In rat atrial ﬁbro-
blasts, colchicine completely blocked both hole-cell and
single-channel currents of mechano-gated channels, acti-
vated by cell mechanical deformations (45). Mechanically
induced potentials in rat atrial ﬁbroblasts have also been
shown by the same researchers to depend on actin and
tubulin polymerization (46). In another study, the modula-
tion of L-type I (Ca) current by muscarinic and beta-
adrenergic agonists required an intact microtubule network
(47) and was affected in a colchicine environment.
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induction and maintenance of AF (48).
Colchicine in Coronary Artery Disease
Traditionally, acute coronary syndromes (ACS) were
considered the clinical manifestation of an intra-coronary
thrombotic event, usually resulting from erosion or rupture
of an unstable atherosclerotic plaque that caused platelet
aggregation and partial or total vessel occlusion. Over the
past years, however, this has proven an incomplete depiction,
with more attention being given to the role of inﬂammation
(49,50), both during plaque formation (51) and after plaque
rupture (52). One of the realizations of this notion has been
the addition of high-dose statin therapy to standard ACS
treatment, believed to be beneﬁcial not only thanks to its
lipid-lowering effects but also due to its anti-inﬂammatory
properties (53,54). While research for better antiplatelet
drugs has been extensive, with new drugs such as ticagrelor
and prasugrel being approved for use in ACS, anti-
inﬂammatory treatment research has not progressed, espe-
cially as corticosteroids and NSAIDS have proved to be
harmful in the setting of ACS (55). Colchicine with its
unique anti-inﬂammatory mechanism and potential for
long-term use could theoretically be a candidate to ﬁll this
gap, especially after it was found that colchicine treatment
was accompanied by a reduction in high-sensitivity C-
reactive protein independent of aspirin and atorvastatin in
patients with stable coronary artery disease (CAD) (56).
A large prospective, randomized, observer-blinded
endpoint trial by Nidorf et al. (57) (LoDoCo [Low Dose
Colchicine] study) examined the efﬁcacy of continuous
low-dose colchicine treatment in patients with stable CAD.
The administration of 0.5 mg colchicine per day in addition
to standard CAD therapy proved effective in reducing the
composite of ACS, out-of-hospital cardiac arrest or non-
cardioembolic ischemic stroke (5.3% vs. 16%, p < 0.001;
number needed to treat: 11). The difference was predomi-
nantly driven by a marked decrease in ACS in a median
follow-up of 3 years. When excluding patients who did not
tolerate or refused to take the drug, results were even more in
favor of colchicine (4.5% vs. 16%).
In another recent study by Crittenden et al. (58), patients
under treatment with colchicine for gout prophylaxis had
a lower risk for myocardial infarction in comparison to gout
patients who were not treated with colchicine. Although
results were close to borderline in terms of statistical
signiﬁcance in favor of colchicine (myocardial infarction
1.2% in the colchicine vs. 2.6% in the no-colchicine group,
p ¼ 0.03), this is to be expected as this retrospective study
spanned 1 year only and was not limited to patients with
known CAD, who would potentially draw the most beneﬁt.
Only 1 relatively small study examined the effects of
colchicine in the setting of ACS (59). In this pilot study, 80
patients were followed-up for 30 days after an ACS or acute
ischemic stroke episode. The study examined whetherpatients on colchicine showed any decrease in high-
sensitivity CRP and platelet aggregation compared with
patients on placebo. No difference was shown, even though
the colchicine dose was moderate (1 mg/day). There were no
deaths during follow-up. Potential explanations for these
results are that inﬂammation suppression by colchicine may
be less pronounced in the setting of an ACS, inﬂammation
may play a relatively minor role after plaque rupture in
contrast to plaque formation and destabilization, or that
colchicine was unnecessary for inﬂammation suppression in
patients taking high doses of statins as part of ACS treat-
ment. The authors, however, did not specify how many
hours after ACS diagnosis colchicine was administered or
what treatment ACS patients were subjected to (percuta-
neous coronary intervention [PCI] or thrombolysis). Patient
numbers were also inadequate to detect evidence of clinical
beneﬁt or harm, therefore leaving the role of colchicine in
ACS undecided.
The effects of colchicine on stable CAD may not be
completely attributable to inﬂammation suppression. Patients
with familial Mediterranean fever who were treated with
colchicine showed a reduction in biomarkers related with
vascular injury independently of decreased inﬂammatory acti-
vity, as assessed by high-sensitivity CRP (60). In in vitro
experiments, colchicinehas alsobeen shown to reduce thrombin-
induced platelet aggregation in a concentration-dependent
manner (61,62). Mean platelet volume (MPV), a marker of
platelet activity and predictor of cardiovascular risk (63–65), was
reduced in patients taking colchicine (66) and was negatively
correlated with the duration of colchicine treatment (67) in
patients with familial Mediterranean fever. The same results
were seen in pediatric patients (68,69). It is not clear, however, if
colchicine effects on MPV are direct or the result of inﬂamma-
tion suppression or even if there is any clinical signiﬁcance in
these ﬁndings. The only study that directly assessed platelet
aggregation 30 days after an ACS in patients taking colchicine
showed no difference from the placebo group (59). These
patients though were already under dual antiplatelet therapy, so
these results cannot be safely extrapolated in a population with
stable CAD under aspirin only, who were shown to beneﬁt
from colchicine administration for primary prevention of ACS
(57).
Colchicine and angioplasty. Coronary artery restenosis
after PCI remains a serious problem. Neointimal hyperplasia
and local inﬂammation are key components of the restenosis
process (70). Colchicine, with its antimitotic and anti-
inﬂammatory properties (11), is theoretically attractive as
an agent that could prevent restenosis. Although a relatively
recent study in a dog model had encouraging results (71),
experiments in the pre-stent era were disappointing. Two
clinical studies evaluating colchicine failed to show beneﬁt.
O’Keefe et al. (72) studied patients who underwent plain
balloon angioplasty and found restenosis in 45% of patients
in the placebo-treated group compared with 41% in the
colchicine-treated group (nonsigniﬁcant difference), and
similar results were reported by Freed et al. (73).
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1823The advent of bare-metal and especially drug-eluting
stents marked a new era for angioplasty, with substantially
lower rates of restenosis (74,75). However, even in the
modern era there are patient populations that are still
plagued by high restenosis rates. Our group set out to study
the effect of colchicine in diabetic patients who underwent
PCI and could not, for various reasons, have a drug-eluting
stent implanted, and received a bare-metal stent instead
(76). In-stent restenosis rate was shown to be less than one-
half in the colchicine group (16% vs. 33%) compared with
placebo at 6 months after PCI, with a similar beneﬁt in
terms of lumen area loss, as determined by intravascular
ultrasound. The authors suggested that the discrepancy with
previous studies was due to the difference in mechanisms of
vessel restenosis after plain old balloon angioplasty and in-
stent restenosis. In balloon-only angioplasty, neointimal
hyperplasia is only partly responsible for restenosis, while
artery elastic recoil and remodeling play a substantial role in
the restenotic process. Colchicine cannot be expected to
have any effect on recoil or remodeling. In contrast, in-stent
restenosis is almost exclusively due to neointima formation
(77–79). Although results were favorable for colchicine in
this study, no clinical outcomes were measured. It is there-
fore too early to suggest a role for colchicine in post-PCI
treatment.
Pre-clinical hints for other potential uses. Although this
review focused on clinical studies, there are several in vitro
and animal experiments where colchicine was shown to have
important effects on myocardial cells in different settings, not
related to inﬂammation but rather to microtubule disruption.
Colchicine attenuates pressure-overload heart failure in dogs
(80) and rats (81,82). These results are relevant with the fact
that microtubules seem to play a pivotal role in cardiac
hypertrophy progression (83,84). On the cellular level,
colchicine reduced myocardial cell stiffness in normal rat
cardiomyocytes (85) and a hamster model of congestive heart
failure (86). Colchicine also increased Caþþ currents in rat
cardiac cells (87,88). All these results point toward novel
possible areas of clinical studies for colchicine, namely
arrhythmias, heart failure, and cardiac hypertrophy.
Conclusions
Over the past few years, colchicine has gained momentum in
cardiovascular medicine, being tested in a variety of clinical
settings. In addition to known “traditional” indications,
namely pericarditis, novel potential settings where colchicine
could be beneﬁcial, including AF and CAD, are actively
researched. Colchicine is a unique drug: No other medica-
tion with potent anti-inﬂammatory action has been shown
to be suitable for safe, long-term use (up to 3 years in the
LoDoCo study) in patients with cardiovascular disease.
However, considering the complex cross-talk between the
multifarious inﬂammatory mediators, one could argue that
therapies with targeted immunomodulatory effects would be
more attractive (from a pathophysiologic perspective) thanagents with broad biological actions. This is something that
remains to be investigated. In any case, the results of recent
studies with colchicine are encouraging and suggest that it
may just be worth the effort exploring the full potential of
this ancient drug.
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